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Objectives: Basic Fibroblastic Growth Factor (bFGF) is a powerful mitogen for smooth muscle cells and has been 
implicated in the genesis of Myointimal hyperplasia. The aim of this study was to determine the release of bFGF by veins 
in different haemodynamic conditions. 
Design and setting: Laboratory animal study. 
Materials: In 39 Lewis rats, a 1 cm long segment of inferior vena cava was inserted at the level of the abdominal aorta. 
The segments of inferior vena cava were obtained from syngenic Lewis rats. Arterial Vein Grafts (AVG) were harvested 
after 4 weeks (AVG 4) and 12 weeks (AVG 12). In 16 animals the arterial vein grafts were explanted 4 weeks after the initial 
operation and reimplanted (Reimplanted Vein Grafts: RVG) in syngenic Lewis rats as venous-venous bypass grafts at the 
level of the left iliac vein and harvested after 2 weeks (RVG 2) and 8 weeks (AVG 8). 
Outcome measures: The tissue was studied in organ culture in a serum-free system for (1) release of bFGF (immunoassay) 
and (2) mitogenic activity of the conditioned media. Scanning electron and light microscopy studies were also 
performed. 
Results: bFGF release by veins increased significantly (p < 0.01) when veins were inserted in the arterial circulation, and 
decreased significantly (p < 0.01) when grafts where reimplanted in the venous ystem, bFGF release (ng/cm2): 
Control AVG (4 weeks) AVG (12 weeks) RVG (2 weeks) RVG (8 weeks) 
55 + 7 295 + 20 340 +_ 18 86 + 10 92 +_ 12 
Conclusion: Vein inserted in the arterial circulation release a higher quantity of bFGF. This could explain in part, the 
formation of myointimal hyperplasia in arterial vein graft. 
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Introduction 
Arterial vein bypass grafting is a common procedure 
in cardiac and peripheral vascular surgery. Approx- 
imately 20% of all vein grafts develop stenosis and 
nearly 80% of these lesions occur in the first year after 
surgery, often because of myointimal hyperplasia 
(MH).I-4 
The basic histopathology of MH is a proliferative 
response of smooth muscle cells (SMC). In MH, 
smooth muscle cells proliferate and migrate from the 
media to the intima. 5'6 This abnormal proliferative 
response can lead to vein wall thickening and graft 
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occlusion by reducing the flow channel diameter, 
especially in small calibre veins. The factors leading to 
MH in arterial vein grafts are ill-defined. Growth 
factors, cytokines and other chemicals induce and 
regulate numerous cell functions during the process of 
MH and atherogenesis. They may act in cell recruit- 
ment and migration, cell proliferation and the control 
of protein synthesis, including extracellular matrix 
proteins. 
One of the best characterised mitogen for smooth 
muscle cells is basic Fibroblastic Growth Factor 
(bFGF). bFGF is a member of heparin binding mito- 
gens and is widely distributed. SMC and endothelial 
cells contain bFGF in large quantities. 7-9 Recently 
Lindner and Reidy have shown that bFGF is a potent 
pharmacological stimulant of smooth muscle cells 
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growth in injured arteries. In addition, they have 
shown that the administration of a blocking antibody 
to bFGF inhibits the proliferation of SMC, in balloon 
injured carotid artery by 80%. l° The results of their 
study suggest that endogenous bFGF is a major 
mitogen controlling the growth of vascular smooth 
muscle cells following injury. 
In our laboratory we found that, in vitro, increasing 
shear stress induce the release of higher levels of bFGF 
by arterial smooth muscle cellsJ ~ In vivo, wall shear 
stress is directly proportional to flow velocity and 
inversely proportional to the cube of the vessel radius. 
Autogenous veins when inserted into the arterial 
circulation are subjected to increased blood pressure 
and higher shear stress compared to haemodynamic 
conditions of the native venous system. Thus, theoret- 
icall)~ bFGF could be responsible for MH formation in 
arterial vein graft. Attempts have been made to induce 
the structural alterations of the intimal hyperplasia 
and then to produce its regression by altering the 
haemodynamic characteristics of arterial blood 
flow.12'lBDavis et al. investigated the regression of 
intimal hyperplasia in arterial vein grafts once reim- 
planted in the venous circulation. 14 They correlated 
the reduction of intimal hyperplasia with the restora- 
tion of endothelium-dependent relaxing factor. In 
recent experiments we found that vein grafts when 
inserted in the arterial circulation release a higher 
quantity of growth factors including bFGF. This 
phenomenon could explain in part, the formation of 
MH in arterial vein grafts. 
The purpose of this study was to determine the 
release of bFGF by vein grafts when inserted into the 
arterial circulation and by arterial vein grafts when 
reimplanted in the venous system. The relationship 
between the release of bFGF and the structural 
changes of vein graft was also investigated. 
Material and Methods 
Experimental Design 
In 39 male inbred Lewis rats (average weight 250 g), a 
1 cm long segment of inferior vena cava was inserted 
into the arterial system, at the level of the abdominal 
aorta. The segments of inferior vena cava were 
obtained from syngenic Lewis rats (same genetic 
pattern). Arterial Vein Grafts (AVG) were harvested 
after 4 weeks (AVG 4:15 animals) and 12 weeks (AVG 
12:8 animals). In 16 animals the arterial vein grafts 
were explanted 4 weeks after the initial operation and 
reimplanted (Reimplanted Vein Grafts: RVG) in syn- 
genic Lewis rats as venous-venous bypass grafts at the 
level of the left iliac vein and harvested after 2 weeks 
(RVG 2:8 animals) and 8 weeks (AVG 8:8 animals). At 
the time of harvest, segments of similar dimensions of 
endogenous inferior vena cava, aorta or left iliac vein 
above and below the graft were removed. 
Operative Procedure 
The animals were anaesthetised with intramuscular 
Xylazine (3 mg/kg) and intramuscular Ketamine (50 
mg/kg) supplemented by intraperitoneal Ketamine 
for maintenance. Surgery was performed using an 
operating microscope (Zeiss OPMI 7-D). 
A 1 cm long segment of supra diaphragmatic 
inferior vena cava was obtained from donor rats. The 
chest was opened, and the supra diaphragmatic 
portion of inferior vena cava was identified and 
excised (Fig. 1A). The animal was sacrificed at this 
time. The vein was kept moist in Dulbecco Modified 
Eagle Medium (DMEM) for approximately 20 rain, 
while the receiving rat was anaesthetised and the 
abdominal aorta identified, and both proximal and 
distal control obtained. The vein grafts were inserted 
with end to end anastomoses u ing 10-0 monofilament 
nylon sutures (Ethicon Inc) (Fig. 1B). The same 
microsurgical procedure and materials were used to 
fashion venous-venous bypass grafts at the level of the 
left iliac vein (Fig. 1C). The total ischemia time was 
between 30 and 45 min. Graft patency was evaluated 
at the time of surgery and thereafter by weekly 
palpation of the femoral pulse in AVG or inspection 
for a swollen leg. Throughout each procedure, care 
was taken to avoid unnecessary damage of the graft 
tissue. 
Harvesting procedure 
With the animal under deep anaesthesia, bdomen 
and chest were opened. The aorta or the left iliac vein 
above and below the graft, the vein graft and a 
segment of same dimensions of supra diaphragmatic 
Inferior Vena Cava were exposed and excised. In each 
group, three grafts were used for scanning electron 
and light microscopy. The other grafts were examined 
for bFGF production. 
Histologic Examination 
Grafts were perfusion fixed with an initial infusion of 
Hanks balanced salt solution, followed by 10% formal- 
dehyde. Transverse 5 ~zm sections were stained with 
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Haematoxylin and Eosin or with elastic tissue stains 
by means of standard techniques. Intimal and medial 
thickness as well as luminal radius were defined and 
calculated by videomorphometry (Quantimet 500) at 
different levels of vein graft. 
For scanning electron microscopy, specimens were 
fixed in 2.5% glutaraldehyde made up in 0.1 mol/1 
cacodylate buffer (pH 7.2), rinsed several times and 
left for 1 h in the same buffer. The specimens were 
then fixed for 1 h in osmium 1%, dehydrated in 
ascending concentrations of ethanol (15% to 100%), 
critical point dried in CO2, mounted in specimen 
stubs, and sputter-coated with gold-palladium accord- 
ing to standard techniques. All specimens were 
examined in a scanning electron microscope (Hitachi 
S. 570) at an accelerating voltage of 15 KV. 
Organ culture 
The arterial, vein and graft segments were rinsed 
thoroughly for 10 minutes with DMEM supplemented 
with antibiotics (Gentamycin 200/~g/ml, Streptomy- 
cin 100/~g/ml, Penicillin 100 IU/ml). The vessels were 
then opened longitudinally and placed in organ 
culture. The specimens were placed in 48-well Costar 
tissue culture plates for organ culture.The tissue was 
incubated in 1 ml of DMEM supplemented with 
antibiotics (Gentamycin 200/~g/ml Streptomycin 50 
izg/ml, Penicillin 50/~g/ml) at pH 7.4. The tissue was 
incubated for 5 days at 37°C in a 5% CO2 atmosphere. 
Aliquots of conditioned medium were collected at 24, 
72 and 120 h and centrifuged for 5 min at 15000 rpm 
and the supernatant stored at -80°C for assay of 
mitogenic activity and assay of bFGF release. 
Assay for mitogenic activity of conditioned media
Sub-confluent bFGF receptor-bearing Swiss 3T3 cells 
were used to assay the DNA synthesis timulation 
activity of the conditioned media. The cells were 
plated in 96 wells plates (Flacon Plastic) at a density of 
4 × 104 cells/ml in 200~1 of DMEM supplemented 
with 0.1% Foetal Calf Serum. Conditioned serum free 
media from AVG and RVG at different hours and 
control media were added to Swiss 3T3 cells (20 tzl). 
The positive controls received an equivalent volume 
of DMEM plus human recombinant bFGF (Boehringer 
Mannheim, Germany); negative controls received 
serum-free DMEM. Tritiated thymidine (0.5 tzCi per 
well plate) was added, the cultures were incubated for 
18 h and collected on Skatron Filters (Skatron Instru- 
ments Inc., Sterling, VA, U.S.A.) for radioactivity 
determination in a LKB scintillation counter. 
A B C 
Fig. 1. Schematic drawing of the operative procedure. A segment of supradiaphragmatic inferior vena cava from syngenic Lewis rat (A) was 
interposed atthe level of the abdominal orta (B). 4 weeks after the initial operation the arteriaal vein graft was reimplanted at the level 
of left iliac vein (C). 
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Analysis of reduction of mitogenic activity by anti-bFGF 
antibody 
Measurement of the Swiss 3T3 cells DNA synthesis- 
stimulating activity of the conditioned media from 
vein grafts and control veins was repeated in presence 
of an excess of monospecific anti-bFGF antibody 
produced in our laboratory (50]zg/ml). Tritiated thy- 
midine was again added and the cultures were 
incubated for 18 h. After further processing, the 
radioactivity was measured. 
bFGF assay in the conditioned media 
The presence of bFGF molecules in the serum-free 
conditioned media from vein grafts and control veins 
was determined by inhibition antibody-binding assay. 
A dilution of anti-bFGF mouse monoclonal antibody 
that showed about 50% maximal reactivity against 
bFGF was incubated with various dilutions of con- 
ditioned media in 400/zl tubes precoated with PBS- 
gelatine 2%. After 20 h of incubation at 4°C, staphylo- 
coccus A was added, and the immunoaggregates were 
removed by centrifugation. The residual antibody- 
binding activity in the supernatant was measured by 
enzyme-linked immunosorbent assay (ELISA). 13 Plas- 
tic wells (96 wells, Falcon Plastic) were coated with 
bFGF (10 ng per well) for 8 h at 4°C. Plates were then 
washed twice with PBS and saturated with PBS- 
gelatin 1% for 2 h at 37°C. Washed wells were then 
filled with 50/~1 per well of supernatant obtained after 
immunoprecipitation. After 2 h of incubation at 37°C 
the wells were washed with PBS-gelatine 0.1%. Perox- 
idase-labelled goat anti-mouse immunoglobulin anti- 
body was added. After 60 minutes of incubation at 
37°C the plate was washed three times in PBS-gelatine 
0.1% and once in distilled water. Finally O-Phenylene- 
diamine Dihydrochloride (0.4 mg/ml) (SIGMA, St. 
Louis, MO, U.S.A.) was added as substrate for the 
enzyme. Bound-specific antibody was quantitatively 
measured by optical density reading at 492 nm with a 
spectrophotometer (Beckman Instruments, Inc., Brea, 
CA, U.S.A.). We used mouse anti-bFGF monoclonal 
antibody as positive control and antibody without 
specificity as negative control. 
The amount of bFGF in the conditioned media was 
quantified by comparison with a standard curve 
obtained using known quantities of human recombi- 
nant bFGF. 
Statistical analysis 
Statistical analysis was performed with Statview 
software (Abacus Concepts, Inc. Berkeley, CA, U.S.A.) 
on a Macintosh Powerbook microcomputer (Apple 
Computer, Inc., Cupertino, CA, U.S.A.) Data were 
expressed as mean + S.D. Differences between the 




At harvest, arterial vein grafts were firm and rigid, 
compared with control veins. Twelve weeks after 
surgery, AVG showed an increase in external diameter 
compared with AVG 4, whereas 8 weeks after the 
reimplantation, RVG showed a decrease in external 
diameter compared with RVG 2. 
Microscopically, intact endothelial cells were pre- 
sent on the surface of AVG and RVG as well as in 
control vein (Fig. 2). There were scattered platelets and 
leukocytes adhering to endothelial cells. Myointimal 
hyperplasia was present in all the arterialised vein 
grafts; large amount of connective tissue and several 
layers of smooth muscle cells were present. In the 
reimplanted veins, connective tissue was preponder- 
ant over smooth muscle cells. Control veins consisted 
of a single layer of endothelial cells and a few layers of 
smooth muscle cells. Table 1 shows the total area of 
intima and media (/~m 2) of AVG, RVG and control 
vein. In arterial vein grafts, intima-media area 
increased significantly compared with control vein 4 
and 12 weeks after the initial operations (p < 0.01) (Fig. 
3). Two weeks after reimplantation, vein grafts 
showed a decrease in the total area of intima and 
media as compared with the arterial vein grafts, and 
the difference became significant after 8 weeks 
(p < 0.05). RVG after 8 weeks showed a significant 
reduction in lumenal radius as compared with RVG2 
and AVG (p < 0.01) (Fig. 4). 
Mitogenic activity of the conditioned media nd its 
reduction by anti-bFGF antibody 
Addition of serum-free conditioned medium from 
AVG 4 and AVG 12 collected after different time 
intervals (12, 72 and 120 h) of incubation in organ 
culture produced a mean increase of tritiated thymi- 
dine uptake of ten-fold (p < 0.01) and fourteen-fold 
(p<0.01) respectively as compared with negative 
control. Addition of monospecific anti-bFGF to the 
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(A) (B) 
Fig. 2. Scanning electron microscopy of arterial vein graft 4 weeks following implantation (A) and control vein (B). Endothelial ceils form 
the internal surface. 
medium of 3T3 cell cultures exposed to the con- 
ditioned medium from AVG decreased the uptake of 
tritiated thymidine by 55% and 40% in AVG 4 and 
AVG 12 respectively (p< 0.01) (Fig. 5). Two weeks after 
reimplantation i  the venous system, the mean tri- 
tiated thymidine uptake was significantly reduced as 
compared with the level of the vein grafts at the time 
of reimplantation (4 weeks) (p < 0.01). The mitogenic 
activity returned to the level of negative control 
(DMEM) and remained constant in the following 
weeks (RVG 8). Again, addition of monospecific anti- 
bFGF to the medium of 3T3 cell cultures exposed to 
the conditioned medium from RVG decreased the 
uptake of tritiated thymidine (Fig. 6). 
Table 1. Structural changes of vein graft 
Group Intima and media area (~m 2) x 105 
AVG4 16.8_+ 4.47 
AVG12 17.5_+ 3.58 
RVG2 15 + 6.02 
RVG8 5.9 + 3.35 
Control vein 1.9_+ 0.8 
bFGF assay by ELISA 
Table 2 show the release of bFGF from AVG, RVG and 
control veins. The release of bFGF was significantly 
higher in AVG as compared with control vein 
(p < 0.01), and decreased 2 weeks after the reimplanta- 
tion (p<0.01) and remained at approximately the 
same level during the following weeks (8 weeks- 
RVG). 
Discussion 
MH has been implicated as a cause of stenosis and 
possible occlusion in small to midsized arterial recon- 
structive procedures. While findings from numerous 
Table 2. Release of bFGF (ng/cm 2) 
Control vein AVG AVG RVG RVG 
(4 weeks) (12 weeks) (2 weeks) (8 weeks) 
55_+7 295_+20 340_+18 86_+10 92_+12 
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A B C 
Fig. 3. Light microscopy of control vein (A) and arterial vein graft 4 weeks (B) and 12 weeks from implantation (C). Evidence of myointimal 
hyperplasia in vein graft. The intima-media l yer of AVG 4 and AVG 12 was statistically thicker than control vein (p < 0,01). L = lumen. 
(H.E. × 4). 
h' 
A B 
Fig. 4. Light microscopy of reimplanted vein graft 2 weeks (A) and 8 weeks (B) from operation. RVG 8 showed a significant reduction of 
intima-media area as compared with arterial vein graft at he time of harvest for reimplantation (p < 0.05). RVG after 8 weeks showed a 
significant reduction in lumenal radius compared with e 2 weeks-RVG and AVG (p < 0.01). L = lumen (H.E. × 4). 
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clinical reports have outlined the lesion seen at arterial 
reconstruction, 1-4 our understanding of the under- 
lying mechanisms i still at an early stage. 
In a recent article, Gibbons and Dzau expressed the 
emerging concept of vascular remodelling) s They 
considered the vessel wall as an active, integrated 
organ composed of endothelial, smooth muscle, and 
fibroblast cells coupled to each other in a complex 
autocrine-paracrine s t of interactions. The vascu- 
lature is capable of sensing changes within its milieu, 
integrating these signals by intercullular communica- 
tions and changing itself through the local production 
of mediators that influence structure as well as 
function. The results of our study fit their theory 
well. 
Areas of intima and media as well as the lumenal 
radius of vein grafts changes according to different 
haemodynamic onditions. Once inserted into the 
arterial circulation vein grafts are subjected to a higher 
pressure and level of shear stress, release a higher 
quantity of growth factors, including bFGF and 
undergo significant MH. Moreover, the lumenal 
radius increases slightly 4 weeks and, more sig- 
nificantl:~ 12 weeks after the operation. Area of intima 
and media return to the level of control veins when a 
graft implanted for 4 weeks at the level of abdominal 
aorta is returned to venous circulation and harvested 
after an additional 8 weeks. After the same period of 
time, RVG show a decrease in lumenal radius below 
the level of control vein. In RVG, growth factor release 
returned to the level of negative control after 2 weeks 
only, and remain constant during the following 
weeks. 
Two similar recent experiments of reimplanted vein 
grafts in a canine 16 and in a rabbit model 14 showed a 
regression of intimal hyperplasia. Davis et al. sug- 
gested that restoration of endothelium dependent 
relaxing factor-mediated relaxation was responsible of 
MH regression) 4 In our opinion, growth factors, 
including bFGF play a more important role in vascular 
remodelling and in the development of MH. 
According to the theory of Gibbons and Dzau, we 
can recognise four different components in the process 







AVG4 AVG12 bFGF DMEM 
Fig. 5. Tritiated thymidine uptake in Swiss 3T3 cells after addition of 
serum-free conditioned medium from AVG 4 and 12 collected after 
different time intervals of incubation in organ culture. DMEM: 
negative control. Human recombinant bFGF: positive control. AVG 
4 and AVG 12 showed a mean increase of tritiated thymidine uptake 
of tenfold (p<0.01) and fourteenfold (p<0.01) respectively as 
compared with negative control. Addition of anti bFGF (empty 
column) to the medium of 3T3 cell cultures exposed to the 
conditioned medium from AVG 4 and AVG 12 decreased the uptake 
of tritated thymidine by 55% and 40% respectively ( < 0.01). 
20000 
10000 
RVG 2 RVG 8 bFGF DMEM 
Fig. 6. Tritiated thymidine uptake in Swiss 3T3 cells after addition of 
serum-free conditioned medium from vein graft reimplanted in the 
venous circulation for 2 weeks (RVG 2) and for 8 weeks (RVG 8) and 
collected after different time intervals of incubation i  organ culture. 
DMEM: negative control. Human recombinant bFGF: positive 
control. In RVG the mean tritiated thymidine uptake was sig- 
nificantly reduced as compared with the level of the vein grafts at 
the time of reimplantation (4 weeks) (p < 0.01). The mitogenic 
activity returned to the level of negative control (DMEM). Addition 
of monospecific anti-bFGF (empty column) to the medium of 3T3 
cell cultures exposed to the conditioned medium from RVG 
decreased the uptake of tritiated thymidine. 
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changes in haemodynamic conditions (sensors); the 
relay of signals within the cell and to adjacent cells 
(transducers); the synthesis and release or activation 
of substances that influence cell growth, death and 
migration or the composition of the extracellular 
matrix (mediators); and the resultant structural 
changes in vessel wall (both cellular and noncellular 
components). 
The results of this study suggest that bFGF released 
in AVG and RVG is mainly derived from EC and SMC. 
Although macrophages and leukocytes may produce 
bFGF, neither type of cells appeared to account of 
differences observed in bFGF release between AVG, 
RVG and control vein. bFGF has a number of 
properties that are similar to other factors such as 
binding to plasma membrane receptors that are 
tyrosine kinases, multipotent functions, and unique 
expression during development. 7 bFGF does have 
several unique properties that differentiate it from 
most other growth factors. One of these is the lack of 
a signal peptide normally required for vectorial 
translation into the endoplasmic reticulum and secre- 
tion. A second property is that bFGF exists in two 
different forms, an high molecular weigh form 
(HMW) and an 18 kDA form. 17 The subcellular 
distribution of. these different forms of bFGF is not 
equivalent, ls'~9 The intracellular localisation raises 
question concerning how and where bFGF is 
released. 
It has been shown that severe injury and/or all lysis 
results in release of bFGF. 2° However, in our organ 
culture the tissue remain viable, as observed in 
previous studies using thymidine uptake. Alterna- 
tively, Yu et al. 21 found bFGF immunoreactive cyto- 
plasmatic vesicles in bovine EC and in some instances 
the vesicles were seen to fuse with the plasma 
membrane, appearing to discharge their immunor- 
eactive bFGF at the luminal surface. Recently, Rifkin et 
al. 22 has shown modulation of cellular function by 
altering bFGF levels on isolated, single living cells. 
Under these conditions all bFGF must come from the 
cell under observation, and the possible contribution 
from dying cells is eliminated. The result of this study 
indicate that bFGF is released from living cells and can 
act as a true autocrine factor. 
In conclusion, we suggest hat increase release of 
bFGF by arterial vein grafts might be responsible for 
MH and wall thickening. Serial studies in time 
showed that bFGF production is probably the cause of 
MH and not the opposite. RV6 harvested 2 weeks after 
surgery had still evidence of MH, but bFGF release 
was low, similar to control veins. These findings 
support the view that pharmacological intervention 
directed to reduce growth factors release might be 
beneficial in preventing MH in arterial vein grafts. 
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